<DOC>
	<DOCNO>NCT00205231</DOCNO>
	<brief_summary>This pilot study investigate safety effect etanercept HIV infection study HIV replication immune function ( measure CD4 count ) individual HIV infection .</brief_summary>
	<brief_title>A Pilot Study Examine Feasibility Effect Tumor Necrosis Factor ( TNF ) Inhibition HIV Disease</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Adults great 18 year age document HIV infection Highly active antiretroviral therapy ( HAART ) regimen define Department Health Human Services guideline ; stable regimen 12 week . CD4 great 200 time study enrollment Stable monitoring lab ( hematology survey differential , ALT , creatinine ) Absolute neutrophil count within normal limit AIDS define illness within last 6 month Acute bacterial , viral , fungal infection within last 1 month , history recur infection Women pregnant nursing Hypersensitivity etanercept Previous use etanercept Acute malignancy last 5 year exclude situ cervical cancer ( CA ) common skin cancer ( non melanoma ) History active latent tuberculosis History demyelinate nerve disease History seizure disorder Latex allergy Subject follow laboratory value within 30 day baseline : hemoglobin concentration &lt; 10.0 g/dl men &lt; 9.0 g/dl woman platelet count &lt; 75,000/mm3 AST ALT &gt; 5x upper limit normal ( ULN ) serum creatinine &gt; 2.5x ULN serum pancreatic amylase &gt; 1.5 ULN Subject require treatment immunomodulating agent , systemic corticosteroid , interleukin , vaccine , interferon Subjects chronically use overthecounter ( OTC ) prescription medication ( except vitamin ) must change regimen switch medication within 3 day drug administration discharge study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>HIV</keyword>
</DOC>